AIM ImmunoTech Provides Routine Update on Annual Filings

AIM ImmunoTech (NYSE American: AIM) disclosed that its audited consolidated financial statements for the year ended December 31, 2025 include an independent auditor's going concern emphasis of matter.

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) disclosed that its audited consolidated financial statements for the year ended December 31, 2025 include an independent auditor's going concern emphasis of matter. This disclosure is required by NYSE American Section 610(b) and does not amend prior filings.

The company said management remains confident in its ability to raise funds and highlighted positive progress in the Phase 2 DURIPANC study of Ampligen plus durvalumab for metastatic pancreatic cancer; the next DURIPANC update is expected in June 2026.

Positive

• DURIPANC Phase 2 showed reported positive progress
• Next DURIPANC update scheduled for June 2026

Negative

• Auditor going concern emphasis noted in 2025 audited financials

Argus Apr 14 session

+8.96% close to close 0.1x rel. volume Open Argus

Details

News Market Reaction – AIM

On Apr 14, the first trading day after this news, AIM closed 8.96% above the previous close.

Data tracked by StockTitan Argus for the Apr 14 session.

Key Figures

Fiscal year end: December 31, 2025 Phase: Phase 2 Next DURIPANC update: June 2026

Fiscal year end

December 31, 2025

Audit report with going concern emphasis for FY 2025 statements

Phase

Phase 2

DURIPANC study of Ampligen + Imfinzi in metastatic pancreatic cancer

Next DURIPANC update

June 2026

Expected timing of next Phase 2 DURIPANC update

Historical Context

5 past events · Latest: Apr 09

5 events

1. Apr 09

   Investor event announcement

   24h Move

   -6.2%

   Virtual investor Closing Bell event and corporate overview scheduled.

2. Mar 18

   Patent approval

   24h Move

   +43.7%

   Final approval of Japanese patent for Ampligen with cancer indications.

3. Mar 06

   Rights offering closing

   24h Move

   +4.3%

   Closing of rights offering raising about $1.8M via preferred and warrants.

4. Mar 04

   Rights offering results

   24h Move

   -1.3%

   Preliminary results of rights offering with aggregate $1.8M subscriptions.

5. Mar 02

   Phase 3 planning

   24h Move

   -14.9%

   Agreement to design proposed Phase 3 Ampligen trial in pancreatic cancer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

going concern, phase 2, immune checkpoint inhibitor, metastatic, +3 more

7 terms

going concern financial

"contained an audit report ... with a going concern emphasis of matter."

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

phase 2 medical

"positive progress in the Phase 2 clinical study evaluating Ampligen combined"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

immune checkpoint inhibitor medical

"Ampligen combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi"

An immune checkpoint inhibitor is a type of medicine that helps the body's immune system recognize and attack cancer cells more effectively. It works by blocking certain signals that cancer uses to hide from immune defenses, allowing the immune system to target tumors. This breakthrough has led to new cancer treatments, making immune checkpoint inhibitors an important area of growth and innovation in the healthcare industry.

metastatic medical

"in the treatment of metastatic pancreatic cancer patients with stable disease"

Metastatic describes cancer that has spread from its original spot to other organs or tissues, like weeds moving from one garden bed into several others. For investors, metastatic disease matters because it often requires more complex, long-term treatments, larger clinical trials, and can drive demand for specialized drugs and diagnostics—factors that affect a drug’s development costs, regulatory risk, market size, and potential revenue.

folfirinox medical

"patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study)."

FOLFIRINOX is a combination chemotherapy treatment made up of several anti-cancer drugs given together to treat advanced cancers, most often pancreatic cancer. Investors watch it because its effectiveness, side effects and approval or use guidelines influence sales of the component drugs, demand for alternative therapies, hospital treatment patterns and the financial prospects of companies running clinical trials or selling supportive care for these patients—think of it as a widely used multi-drug toolkit whose performance shapes related markets.

stable disease medical

"metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX"

Stable disease describes a situation in a clinical trial or treatment where a patient’s condition neither meaningfully improves nor worsens—tumors don’t shrink significantly but also don’t grow. For investors, this signal can matter because it shows a therapy may halt progression, which can support regulatory decisions, extend patient benefit and influence a drug’s commercial prospects; think of it as a stalled race where forward movement has paused but relapse hasn’t accelerated.

pd-l1 medical

"combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi"

PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025, contained an audit report from its independent registered public accounting firm with a going concern emphasis of matter. Release of this information is required by Section 610(b) of the NYSE American Company Guide, and does not represent any change or amendment to any of the Company’s filings for the fiscal year ended December 31, 2025.

AIM management is confident in its continued ability to raise funds based on ongoing, promising results in the development of its lead drug, Ampligen, for the treatment of late-stage pancreatic cancer. The Company recently reported positive progress in the Phase 2 clinical study evaluating Ampligen combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study). AIM expects to release the next DURIPANC update in June 2026.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

Forward-Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen^® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen^® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen^® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. No assurance can be given that intention to seek Orphan Drug Designation will result in the granting of that status, nor that the possession of Orphan Drug Designations or any patents means that a drug will receive market approval. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the Registration Statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

Investor Contact:
 
JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AIM (AIM) disclose about its 2025 audited financial statements on April 13, 2026?

The company disclosed an auditor's going concern emphasis of matter in the 2025 audited consolidated financials. According to the company, this disclosure is required by NYSE American rules and does not change or amend prior 2025 filings.

Does the auditor's going concern emphasis mean AIM (AIM) is insolvent?

Not necessarily; a going concern emphasis signals uncertainty about near-term liquidity but is not a determination of insolvency. According to the company, management remains confident in its ability to raise funds based on clinical progress with Ampligen.

What clinical progress did AIM (AIM) report for Ampligen on April 13, 2026?

AIM reported positive progress in the Phase 2 DURIPANC study combining Ampligen with durvalumab for metastatic pancreatic cancer. According to the company, the study targets patients with stable disease after FOLFIRINOX and will have a June 2026 update.

When will AIM (AIM) provide the next DURIPANC study update and what should investors expect?

AIM expects to release the next DURIPANC update in June 2026. According to the company, the update will provide additional clinical progress information on Ampligen combined with durvalumab in metastatic pancreatic cancer patients.

How does the April 13, 2026 filing affect AIM (AIM) shareholders and fundraising prospects?

The filing highlights auditor concern about near-term funding but does not amend prior filings. According to the company, management is confident in raising funds driven by promising Ampligen clinical results and upcoming DURIPANC data.